This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lainka, E.
Right arrow Articles by Niehues, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lainka, E.
Right arrow Articles by Niehues, T.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Human Immunodeficiency Virus...

PEDIATRICS Vol. 110 No. 5 November 2002, pp. e56

ELECTRONIC ARTICLE

Marked Dyslipidemia in Human Immunodeficiency Virus-Infected Children on Protease Inhibitor-Containing Antiretroviral Therapy

Elke Lainka, MD*, Selda Oezbek*, Manfred Falck, MD{ddagger}, Jennifer Ndagijimana, MD* and Tim Niehues, MD*

* Paediatric Immunology and Rheumatology Unit, the Children’s Hospital
{ddagger} Clinical Chemistry and Laboratory Research Unit, Heinrich Heine University, Düsseldorf, Germany

--> Objective. To assess the effects of antiretroviral combination therapy that contains protease inhibitor (PI) on carbohydrate and lipid metabolism in human immunodeficiency virus (HIV)-infected children.

Methods. A cross-sectional, descriptive clinical study was conducted in an outpatient clinic. Thirty-seven HIV-infected children who ranged from 1 to 17 years of age received nucleoside reverse transcriptase inhibitor treatment together with PI (PI group, n = 25) or without PI (non-PI group, n = 12). Age, gender, weight, length, CD4 cell count, and viral load did not differ between groups. Nonfasting total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, lactate, and blood gases were determined. In addition, c-peptide, insulin, hemoglobin A1c, free fatty acids, lipoprotein a, and apolipoproteins A1 and B were evaluated after fasting. PI and non-PI group values were compared with normal values taken from healthy children.

Results. In nonfasting and fasting conditions, children of the PI group had higher total cholesterol (fasting PI group: 235 ± 71 mg/dL; non-PI group: 176 ± 25 mg/dL, mean ± standard deviation), triglycerides (156 ± 89 vs 87 ± 31 mg/dL), and LDL cholesterol levels (159 ± 58 vs 113 ± 23 mg/dL) compared with the non-PI group. High-density lipoprotein cholesterol and apolipoprotein A1 levels did not differ in both groups; there was a trend toward higher apolipoprotein B levels in the PI group. After fasting, 8 (47%) of 17 patients in the PI group presented with hypercholesterolemia as a result of an increase of LDL cholesterol and 11 (65%) had hypertriglyceridemia. It is interesting that the non-PI group showed no pathologic deviations. Compared with normal values, lipoprotein a and free fatty acids were increased in the PI and non-PI groups. Glucose, lactate, blood gases, c-peptide, insulin, and hemoglobin A1c were normal in both groups.

Conclusion. PI-containing antiretroviral treatment of HIV-infected children was associated with hypercholesterolemia, hypertriglyceridemia, and an increase of LDL cholesterol. The long-term complications of dyslipidemia are of major concern in the growing HIV-infected child.

Key Words: antiretroviral therapy • HIV infection • dyslipidemia • carbohydrate metabolism

Abbreviations: HAART, highly active antiretroviral therapy • PI, protease inhibitor • NNRTI, nonnucleoside reverse transcriptase inhibitor • NRTI, nucleoside reverse transcriptase inhibitor • HIV, human immunodeficiency virus • 3TC, lamivudine • AZT, zidovudine • NFV, nelfinavir • DDI, didanosine • d4T, stavadine • RTV, nitonavir, ABC, abacavir • DDC, zalcitabine • SAQ, saquinavir • HDL, high-density lipoprotein • LDL, low-density lipoprotein • Lp(a), lipoprotein a • HbA1c, hemoglobin A1c

Received for publication May 1, 2002; Accepted Jul 16, 2002.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
R. Rosso, A. Parodi, G. d'Annunzio, F. Ginocchio, L. Nicolini, C. Torrisi, M. P. Sormani, R. Lorini, C. Viscoli, and M. Vignolo
Evaluation of insulin resistance in a cohort of HIV-infected youth
Eur. J. Endocrinol., November 1, 2007; 157(5): 655 - 659.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. W. McCrindle, E. M. Urbina, B. A. Dennison, M. S. Jacobson, J. Steinberger, A. P. Rocchini, L. L. Hayman, and S. R. Daniels
Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing
Circulation, April 10, 2007; 115(14): 1948 - 1967.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. E Temple, K. I Koranyi, and M. C Nahata
Lipodystrophy in HIV-Infected Pediatric Patients Receiving Protease Inhibitors
Ann. Pharmacother., September 1, 2003; 37(9): 1214 - 1218.
[Abstract] [Full Text] [PDF]